TY - JOUR
T1 - HLA sensitization is associated with an increased risk of primary graft dysfunction after heart transplantation
AU - Han, Jiho
AU - Rushakoff, Josh
AU - Moayedi, Yasbanoo
AU - Henricksen, Erik
AU - Lee, Roy
AU - Luikart, Helen
AU - Shalakhti, Omar
AU - Gragert, Loren
AU - Benck, Lillian
AU - Malinoski, Darren
AU - Kobashigawa, Jon
AU - Teuteberg, Jeffrey
AU - Khush, Kiran K.
AU - Patel, Jignesh
AU - Kransdorf, Evan
N1 - Publisher Copyright:
© 2023 International Society for the Heart and Lung Transplantation
PY - 2024/3
Y1 - 2024/3
N2 - Primary graft dysfunction (PGD) is a leading cause of early morbidity and mortality following heart transplantation (HT). We sought to determine the association between pretransplant human leukocyte antigen (HLA) sensitization, as measured using the calculated panel reactive antibody (cPRA) value, and the risk of PGD. Methods: Consecutive adult HT recipients (n = 596) from 1/2015 to 12/2019 at 2 US centers were included. Severity of PGD was based on the 2014 International Society for Heart and Lung Transplantation consensus statement. For each recipient, unacceptable HLA antigens were obtained and locus-specific cPRA (cPRA-LS) and pre-HT donor-specific antibodies (DSA) were assessed. Results: Univariable logistic modeling showed that peak cPRA-LS for all loci and HLA-A was associated with increased severity of PGD as an ordinal variable (all loci: OR 1.78, 95% CI: 1.01-1.14, p = 0.025, HLA-A: OR 1.14, 95% CI: 1.03-1.26, p = 0.011). Multivariable analysis showed peak cPRA-LS for HLA-A, recipient beta-blocker use, total ischemic time, donor age, prior cardiac surgery, and United Network for Organ Sharing status 1 or 2 were associated with increased severity of PGD. The presence of DSA to HLA-B was associated with trend toward increased risk of mild-to-moderate PGD (OR 2.56, 95% CI: 0.99-6.63, p = 0.053), but DSA to other HLA loci was not associated with PGD. Conclusions: Sensitization for all HLA loci, and specifically HLA-A, is associated with an increased severity of PGD. These factors should be included in pre-HT risk stratification to minimize the risk of PGD.
AB - Primary graft dysfunction (PGD) is a leading cause of early morbidity and mortality following heart transplantation (HT). We sought to determine the association between pretransplant human leukocyte antigen (HLA) sensitization, as measured using the calculated panel reactive antibody (cPRA) value, and the risk of PGD. Methods: Consecutive adult HT recipients (n = 596) from 1/2015 to 12/2019 at 2 US centers were included. Severity of PGD was based on the 2014 International Society for Heart and Lung Transplantation consensus statement. For each recipient, unacceptable HLA antigens were obtained and locus-specific cPRA (cPRA-LS) and pre-HT donor-specific antibodies (DSA) were assessed. Results: Univariable logistic modeling showed that peak cPRA-LS for all loci and HLA-A was associated with increased severity of PGD as an ordinal variable (all loci: OR 1.78, 95% CI: 1.01-1.14, p = 0.025, HLA-A: OR 1.14, 95% CI: 1.03-1.26, p = 0.011). Multivariable analysis showed peak cPRA-LS for HLA-A, recipient beta-blocker use, total ischemic time, donor age, prior cardiac surgery, and United Network for Organ Sharing status 1 or 2 were associated with increased severity of PGD. The presence of DSA to HLA-B was associated with trend toward increased risk of mild-to-moderate PGD (OR 2.56, 95% CI: 0.99-6.63, p = 0.053), but DSA to other HLA loci was not associated with PGD. Conclusions: Sensitization for all HLA loci, and specifically HLA-A, is associated with an increased severity of PGD. These factors should be included in pre-HT risk stratification to minimize the risk of PGD.
KW - Calculated panel reactive antibodies
KW - Heart transplantation
KW - Human leukocyte antigen
KW - Primary graft dysfunction
KW - Sensitization
UR - http://www.scopus.com/inward/record.url?scp=85175475928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175475928&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2023.09.017
DO - 10.1016/j.healun.2023.09.017
M3 - Article
C2 - 37802261
AN - SCOPUS:85175475928
SN - 1053-2498
VL - 43
SP - 387
EP - 393
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 3
ER -